Pesquisas alternativas:
oil company » oil companies (Expandir a Pesquisa)
iol complex » l complex (Expandir a Pesquisa), gl complex (Expandir a Pesquisa), mll complex (Expandir a Pesquisa)
company can » company car (Expandir a Pesquisa), company case (Expandir a Pesquisa), company cars (Expandir a Pesquisa)
case new » cases new (Expandir a Pesquisa), cause new (Expandir a Pesquisa), caste new (Expandir a Pesquisa)
a newly » _ newly (Expandir a Pesquisa)
can now » can non (Expandir a Pesquisa), can new (Expandir a Pesquisa), can ngoc (Expandir a Pesquisa)
l com » l como (Expandir a Pesquisa), e com (Expandir a Pesquisa), l con (Expandir a Pesquisa)
_ iol » _ ion (Expandir a Pesquisa), _ iot (Expandir a Pesquisa), _ iop (Expandir a Pesquisa)
l oil » _ oil (Expandir a Pesquisa)
oil company » oil companies (Expandir a Pesquisa)
iol complex » l complex (Expandir a Pesquisa), gl complex (Expandir a Pesquisa), mll complex (Expandir a Pesquisa)
company can » company car (Expandir a Pesquisa), company case (Expandir a Pesquisa), company cars (Expandir a Pesquisa)
case new » cases new (Expandir a Pesquisa), cause new (Expandir a Pesquisa), caste new (Expandir a Pesquisa)
a newly » _ newly (Expandir a Pesquisa)
can now » can non (Expandir a Pesquisa), can new (Expandir a Pesquisa), can ngoc (Expandir a Pesquisa)
l com » l como (Expandir a Pesquisa), e com (Expandir a Pesquisa), l con (Expandir a Pesquisa)
_ iol » _ ion (Expandir a Pesquisa), _ iot (Expandir a Pesquisa), _ iop (Expandir a Pesquisa)
l oil » _ oil (Expandir a Pesquisa)
1
Por Rashid, M, Haskett, J, Parkinson-McGraw, L, Noble, A, Van Limbergen, J, Otley, A
Publicado no J Can Assoc Gastroenterol (2018)
“... is complex and counselling by an expert dietitian is essential. Number of new CD diagnoses is increasing...”Publicado no J Can Assoc Gastroenterol (2018)
Obter o texto integral
Obter o texto integral
Artigo
2
“...Angiopoietin-1 is a promoter of physiological vasculogenesis and angiogenesis because it induces...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
3
Por Andersson, E, Aralaguppe, S, Thebo, L, Sönnerborg, A, Neogi, U, Albert, J
Publicado no Virus Evol (2019)
“...The Swedish HIV-1 epidemic is characterized by a high diversity in HIV subtypes and recombinants...”Publicado no Virus Evol (2019)
Obter o texto integral
Obter o texto integral
Artigo
4
Por Marsland, Anna L., Long, Kristin A., Howe, Chelsea, Thompson, Amanda L., Tersak, Jean, Ewing, Linda J.
Publicado em 2013
“...Objectives (1) To examine the acceptability and feasibility of a stress management intervention...”Publicado em 2013
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
5
Por Hemminger, L, Ibegbu, C, Serventi, J, Burke, J, Occhiogrosso, J, Mohile, N
Publicado no Neuro Oncol (2018)
“... of patients with newly diagnosed gliomas enrolled over 2.5 years at a single academic institution. Caregivers...”Publicado no Neuro Oncol (2018)
Obter o texto integral
Obter o texto integral
Artigo
6
Por Capellades, J., Puig, J., Domenech, S., Diaz, R., Oleaga, L., Pujol, T., Camins, A., Majos, C., de Quintana, C., Balana, C.
Publicado no Neuro Oncol (2017)
“... (stages I, II, and III) integrating tumor location (A, B, C), size (≤5 cm or >5cm), and eloquence...”Publicado no Neuro Oncol (2017)
Obter o texto integral
Obter o texto integral
Artigo
7
Por Hansen, T, Silvester, J, Rigaux, L, Graff, L A, Bernstein, C N, Walker, J R, Duerksen, D
Publicado no J Can Assoc Gastroenterol (2018)
“... for health information. AIMS: In a population of newly diagnosed CD subjects, identify: 1. Alternate...”Publicado no J Can Assoc Gastroenterol (2018)
Obter o texto integral
Obter o texto integral
Artigo
8
Por Carlsson, A, Kockum, I, Lindblad, B, Engleson, L, Nilsson, A, Forsander, G, Karlsson, A-K, Kernell, A, Ludvigsson, J, Marcus, C, Zachrisson, I, Ivarsson, S-A, Lernmark, Å
Publicado em 2011
“... (BMI). DESIGN: The type 1 diabetes high risk HLA-DQ A1*05:01-B1*02:01/A1*03:01-B1*03:02 genotype along...”Publicado em 2011
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
9
Por Zhang, Yunqi, Carrion, Shane A., Zhang, Yangzi, Zhang, Xiaohui, Zinski, Amy L., Michal, Jennifer J., Jiang, Zhihua
Publicado no Int J Biol Sci (2018)
“... newly developed next generation sequencing methods for genome-wide profiling of alternative...”Publicado no Int J Biol Sci (2018)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
10
Por Sessions, October M., Barrows, Nicholas J., Souza-Neto, Jayme A., Robinson, Timothy J., Hershey, Christine L., Rodgers, Mary A., Ramirez, Jose L., Dimopoulos, George, Yang, Priscilla L., Pearson, James L., Garcia-Blanco, Mariano A.
Publicado em 2009
“..., and absence of specific treatment conspire to make DF a global public health threat(1, 2). Given their compact...”Publicado em 2009
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
11
“... to monitor treatment effects and assess patients' needs. Inspection time, a measure of the efficiency...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
12
Por Bacha, J. A., Steino, A., Schwartz, R., Langlands, J., Kanekal, S., Lopez, L. M., Brown, D. M.
Publicado no Neuro Oncol (2017)
“..., which, if successful, would serve as the basis for a New Drug Application (NDA) submission for VAL-083...”Publicado no Neuro Oncol (2017)
Obter o texto integral
Obter o texto integral
Artigo
13
Por Vardy, J, Jenkins, P J, Clark, K, Chekroud, M, Begbie, K, Anthony, I, Rymaszewski, L A, Ireland, A J
Publicado em 2014
“... in standardised treatment pathways, leaflet supported discharge and a virtual fracture clinic review. Patients...”Publicado em 2014
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
14
Por Esparragosa, I, Inoges, S, de Cerio, A L, Espinos, J, Aristu, J, Puigdelloses, M, Alonso, M, Tejada-Solis, S, Díez-Valle, R, Gállego Pérez-Larraya, J
Publicado no Neuro Oncol (2018)
“...BACKGROUND: Immunotherapy is being increasingly investigated as a treatment for glioblastoma (GBM...”Publicado no Neuro Oncol (2018)
Obter o texto integral
Obter o texto integral
Artigo
15
Por Atsawarungruangkit, A, Silvester, J, Weiten, D, Green, K, Wilkey, K, Rigaux, L, Bernstein, C N, Graff, L A, Walker, J R, Duerksen, D
Publicado no J Can Assoc Gastroenterol (2018)
“... to objectively grade GFD adherence. AIMS: To develop a standardized tool to evaluate GFD adherence that can...”Publicado no J Can Assoc Gastroenterol (2018)
Obter o texto integral
Obter o texto integral
Artigo
16
Por Sasseville, V. G., Mansfield, K. G., Mankowski, J. L., Tremblay, C., Terio, K. A., Mätz-Rensing, K., Gruber-Dujardin, E., Delaney, M. A., Schmidt, L. D., Liu, D., Markovits, J. E., Owston, M., Harbison, C., Shanmukhappa, S., Miller, A. D., Kaliyaperumal, S., Assaf, B. T., Kattenhorn, L., Macri, S. Cummings, Simmons, H. A., Baldessari, A., Sharma, P., Courtney, C., Bradley, A., Cline, J. M., Reindel, J. F., Hutto, D. L., Montali, R. J., Lowenstine, L. J.
Publicado em 2012
“... of nonhuman primates, which was followed by presentations of 20 unique case reports of rare or newly observed...”Publicado em 2012
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
17
Por Lebrun, R., Ross, A., Bender, S. A., Qaiumzadeh, A., Baldrati, L., Cramer, J., Brataas, A., Duine, R. A., Kläui, M.
Publicado no Nature (2018)
“... and impervious to external fields. Additionally, they can be operated at THz frequencies3. Although...”Publicado no Nature (2018)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
18
Por Coomans, M B, Dirven, L, van den Bent, M, Bottomley, A, Coens, C, Stupp, R, Weller, M, Reijneveld, J C, Taphoorn, M J B
Publicado no Neuro Oncol (2018)
“...INTRODUCTION: Symptom management in glioma patients remains a challenge, as patients suffer from...”Publicado no Neuro Oncol (2018)
Obter o texto integral
Obter o texto integral
Artigo
19
“...INTRODUCTION: This study evaluated the relationship of MGMT status with first-line (1L) treatment...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
20
Por Dieterich, Daniela C., Hodas, Jennifer J.L., Gouzer, Geraldine, Shadrin, Ilya Y., Ngo, John T., Triller, Antoine, Tirrell, David A., Schuman, Erin M.
Publicado em 2010
“... in situ visualization of new proteins is limited to one or two proteins at a time. Here we describe a...”Publicado em 2010
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo